The investigational cortisol modulator relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian cancer in a phase 3 study.

We recently published 10 Stocks With Effortless Double-, Triple-Digit Gains. Corcept Therapeutics Inc. (NASDAQ:CORT) was one ...

Corcept recently suffered a blow after relacorilant was rejected by the FDA for use in Cushing’s syndrome.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities ...

Corcept Therapeutics, a pharmaceutical company specialising in cortisol-modulating medications, has announced that its ...

Corcept stock rises after a Phase 3 ovarian cancer trial showed longer survival and lower death risk, even as relacorilant ...

Shares of Corcept Therapeutics CORT were up 13.7% on Jan. 22, after the company announced that the phase III ROSELLA study, ...

CHICAGO -- Combining investigational relacorilant with nab-paclitaxel (Abraxane) improved progression-free survival (PFS), and demonstrated a clinically meaningful trend towards an overall survival ...

Investing.com -- Corcept Therapeutics (NASDAQ:CORT) stock surged 45% Thursday after the company announced its Phase 3 trial ...

Corcept Therapeutics (CORT) stock surges after the company said its Phase 3 ROSELLA study for its ovarian cancer drug ...

Shares of Corcept Therapeutics jumped after a trial found its investigational drug helped reduce the risk of death in patients with a treatment-resistent form of ovarian cancer. Shares rose 14% to $41 ...